Skip to earnings analysis
← Back to feed
VRTX FY2026 Q2 RAISED

Vertex Pharmaceuticals Incorporated earnings call

Aug 03, 2026 · 16:30 ET Charlie WagnerDuncan McKechnieReshma Kewalramani
Buzzberg read

Alyftrek surpassing $1B in first-half revenue

Vertex delivered a strong Q2 2026, beating expectations and raising full-year guidance. The company highlighted continued momentum in its CF franchise, the scaling of Casgevi and Journavix, and the pending acquisition of Krenetics to establish a new pillar in rare endocrine diseases. Q2 2026 total revenue grew 12% YoY to $3.3B, with CF revenue up 11%.

Buzzberg read Alyftrek surpassing $1B in first-half revenue Vertex delivered a strong Q2 2026, beating expectations and raising full-year guidance. The company highlighted continued momentum in its CF franchise, the scaling of Casgevi and Journavix, and the pending acquisition of Krenetics to establish a new pillar in rare endocrine diseases. Q2 2026 total revenue grew 12% YoY to $3.3B, with CF revenue up 11%. Read full analysisCollapse analysis

Vertex delivered a strong Q2 2026, beating expectations and raising full-year guidance. The company highlighted continued momentum in its CF franchise, the scaling of Casgevi and Journavix, and the pending acquisition of Krenetics to establish a new pillar in rare endocrine diseases. Q2 2026 total revenue grew 12% YoY to $3.3B, with CF revenue up 11%.

  • Casgevi revenue was $76M, up 150% YoY, and Journavix revenue was $50M, with strong prescription growth.
  • Full-year 2026 revenue guidance raised to $13.1-$13.2B; non-GAAP EPS was $4.73.
  • Acquisition of Krenetics for ~$8.8B net of cash announced, expected to close in Q3 and be accretive to non-GAAP operating income by 2029.
Revenue $3.3339B +12% QoQ
EPS $4.73 +6% QoQ
Gross margin 85.33% reported
Op margin 37.41% reported

What changed this quarter

01
Product Performance

Alyftrek surpassing $1B in first-half revenue

Vertex delivered a strong Q2 2026, beating expectations and raising full-year guidance. The company highlighted continued momentum in its CF franchise, the scaling of Casgevi and Journavix, and the pending acquisition of Krenetics to establish a new pillar in rare endocrine…

02
Launch Momentum

Casgevi revenue up 75% sequentially; more infusions than all of 2025

Q2 2026 total revenue grew 12% YoY to $3.3B, with CF revenue up 11%.

03
Product Performance

Jurnavix Q2 revenue up 70% sequentially; Rx growth 45%

Casgevi revenue was $76M, up 150% YoY, and Journavix revenue was $50M, with strong prescription growth.

04
Regulatory

POVI BLA accepted with November 30 PDUFA date

Full-year 2026 revenue guidance raised to $13.1-$13.2B; non-GAAP EPS was $4.73.

Demand

Demand

Bookings & conversion

Vertex raised full-year revenue guidance, driven by strong performance across CF, Casgevi, and Journavix, despite headwinds from FX and product mix.

Tone · Confident

Management expressed strong conviction in pipeline progress, commercial launches, and the strategic acquisition, emphasizing 'excellent' performance and 'home run' data.

Supply-chain alpha

A1

Vertex expects Gross-to-Net for Journavix to normalize in line with other branded oral medicines by the first half of 2027, later than prior expectations, due to strategic use of a patient support program.

“As a result, we continue to expect Gross2Net to normalize in line with other branded oral medicines, but now in the first half of 2027.”
Duncan McKechnie
A2

Vertex's Type O islet cell program (VX017) is advancing faster than expected, potentially allowing it to launch first or alongside the Type A program (VX880), effectively doubling the market opportunity.

“A silver lining to the pause we took in the Zamyla Cell Type A program is that the Type O program time differential versus Zamyla Cell has shortened.”
Reshma Kewalramani

Forward guidance

RaisedGuidance · revenue to $13.15B · was IN LINE last Q
MetricPeriodRangeMidpointStatus
Gross marginFY202686%86%MAINTAINED
Op marginFY2026$5.65B–$5.75B$5.7BMAINTAINED
RevenueFY2026$13.1B–$13.2B$13.15BRAISED